• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

HLA Induced Refractoriness to Platelet Transfusions

June 16, 2021

Platelet transfusion refractoriness (PTR) is usually caused by non-immune platelet consumption but can also be caused by immune-mediated platelet destruction.  Both donor and recipient product/factors can contribute to immune-mediated PTR, and alloimmunization against class I human leukocyte antigens (HLA) are often involved.  The three main approaches to identifying HLA compatible platelets include using standard serological assays which requires testing several donors’ platelets, using HLA donor registries to find HLA matched platelets, or using antibody specific prediction (ASP) to match predicted HLA epitopes.  ASP-matched platelets are cheaper than HLA matched platelets and require a smaller donor pool.  However, there is currently little data on using ASP-matched platelets and PTR.  To evaluate one center’s ASP strategy in France, researchers retrospectively analyzed the effectiveness of 556 transfusions given to 16 patients who had screened positive for HLA class I antibodies using a threshold of 3000 MFI (Luminix technology).  Corrected count increments were compared at 1 hour and 24 hours post-transfusion for both HLA-matched and non-HLA-matched platelets, depending on availability.   The median CCI 1 hour post transfusion was 9.24 compared to 4.23 for HLA-matched and non-matched platelets (p=0.01), respectively.  No differences in CCI were observed for HLA matched vs non-matched platelets 24 hours post transfusion, most likely due to non-immune causes of platelet destruction.  These data suggest that ASP may be an appropriate method to manage immune PTR.

Reference:

Blandin L, DougéA, Fayard A, Bay JO, et al.  Platelet transfusion refractoriness and anti-HLA immunization.  Transfusion 2021

Filed Under

  • CME
  • Coagulation & Plasma Transfusion
  • News

Recommended

  • Gene Therapy for Hemophilia A Patients Successful

  • Updated FDA Guidance to Reduce Risk of Transmission of Creutzfeldt-Jakob Disease

  • Drones Capable of Delivering Blood Products

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Multifaceted Threats to the Blood Supply from Climate Change

  • Distinct Roles for Differently Aged Platelets

  • Anemia Treatment Bundle Improves Hemoglobin Recovery after Critical Illness

  • Prothrombin Complex Concentrate Is Safe and Effective for Cardiac Surgery Patients with Coagulopathic Bleeding

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley